Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2019 Jun 15;25(10):1984–1992. doi: 10.1016/j.bbmt.2019.06.007

Table 5.

Summary of Adverse Events Regardless of Attribution

Summary of Grade 1 +Adverse Events Regardless of Attribution Number of Evaluable Patients: 63
Patients with a maximum: n (%)
Total
 Grade 1 Event 0 (0.0%)
 Grade 2 Event 0 (0.0%)
 Grade 3 Event 4 (6.3%)
 Grade 4 Event 42 (66.7%)
 Grade 5 Event 17 (27.0%)
Hematologic Adverse Events
 Grade 1 Event 0 (0.0%)
 Grade 2 Event 1 (1.6%)
 Grade 3 Event 6 (9.5%)
 Grade 4 Event 54 (85.7%)
 Grade 5 Event 0 (0.0%)
Non-Hematologic Adverse Events
 Grade 1 Event 0 (0.0%)
 Grade 2 Event 2 (3.2%)
 Grade 3 Event 37 (58.7%)
 Grade 4 Event 7 (11.1%)
 Grade 5 Event 17 (27.0%)

Note: Summaries are based on available patient data